Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

SOLUBLE CD117 (SC-KIT) FOR DIAGNOSIS OF PREECLAMPSIA AND ECLAMPSIA

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Publication Date:
    June 2, 2011
  • Additional Information
    • Document Number:
      20110129551
    • Appl. No:
      12/955762
    • Application Filed:
      November 29, 2010
    • Abstract:
      This disclosure relates to methods of predicting and diagnosing preeclampsia and eclampsia in pregnant subjects. These methods include detecting a decrease of soluble c-kit in a sample obtained from the pregnant subject. A significantly reduced concentration of soluble c-kit in the sample as compared to a gestational age-adjusted control indicates that the pregnant subject will develop or has preeclampsia or eclampsia.
    • Inventors:
      Hubel, Carl A. (Pittsburgh, PA, US); Catov, Janet M. (Pittsburgh, PA, US); Gandley, Robin E. (Gibsonia, PA, US); Roberts, James M. (Pittsburgh, PA, US); Rajakumar, Augustine (Ashland, MA, US)
    • Claim:
      1. A method of predicting or diagnosing preeclampsia or eclampsia in a pregnant subject, or of distinguishing preeclampsia or eclampsia from gestational hypertension in a pregnant subject, the method comprising: quantitating soluble c-kit in a sample obtained from the pregnant subject; wherein a decreased concentration of soluble c-kit in the sample indicates that the pregnant subject will develop or has preeclampsia or eclampsia, or indicates that the pregnant subject has preeclampsia or eclampsia and does not have gestational hypertension.
    • Claim:
      2. The method of claim 1, wherein the sample is a bodily fluid.
    • Claim:
      3. The method of claim 2, wherein the bodily fluid is blood, plasma, or serum.
    • Claim:
      4. The method of claim 1, further comprising comparing the concentration of soluble c-kit in the sample to a gestational age-adjusted control, wherein a reduced concentration of soluble c-kit in the sample as compared to the control indicates that the pregnant subject has preeclampsia or eclampsia, and does not have gestational hypertension.
    • Claim:
      5. The method of claim 1, wherein the pregnant subject is a veterinary subject.
    • Claim:
      6. The method of claim 1, wherein the pregnant subject is a human subject.
    • Claim:
      7. The method of claim 6, wherein the pregnant subject is in the second or third trimester of pregnancy.
    • Claim:
      8. The method of claim 7, wherein the pregnant subject is at least eighteen weeks pregnant.
    • Claim:
      9. The method of claim 1, wherein the control is the concentration of soluble c-kit in a sample from a pregnant subject that does not have preeclampsia or eclampsia.
    • Claim:
      10. The method of claim 1, wherein the control is the concentration of soluble c-kit in a sample from a gestationally-matched pregnant subject that does not have preeclampsia or eclampsia, or is a standard value.
    • Claim:
      11. The method of claim 1, wherein the sample is a maternal blood, plasma, or serum sample.
    • Claim:
      12. The method of claim 1, wherein the sample is an umbilical cord blood, plasma, or serum sample.
    • Claim:
      13. The method of claim 1, wherein quantitating soluble c-kit comprises: contacting the sample with an antibody, under conditions sufficient to form an immune complex with soluble c-kit, and determining the quantity of the immune complex.
    • Claim:
      14. The method of claim 13, wherein the antibody is labeled.
    • Claim:
      15. The method claim 14, wherein the label is a radioisotope.
    • Claim:
      16. The method claim 14, wherein the label is an enzyme.
    • Claim:
      17. The method of claim 13, wherein quantitating comprises the use of radioimmunoassay.
    • Claim:
      18. The method of claim 13, wherein quantitating comprises the use of ELISA.
    • Claim:
      19. The method of claim 1, further comprising quantitating soluble fms-like tyrosine kinase-1 or free placental growth factor in the sample, wherein a significant elevation in soluble fms-like tyrosine kinase-1, a significant reduction in free placental growth factor, or both, in the sample compared with a control indicates the pregnant subject has preeclampsia or eclampsia.
    • Claim:
      20. The method of claim 1, further comprising quantitating circulating endothelial progenitor cells in the sample from the subject, wherein a significant reduction in circulating endothelial progenitor cells compared with a control indicates the pregnant subject has preeclampsia or eclampsia.
    • Claim:
      21. The method of claim 20, wherein quantitating circulating endothelial progenitor cells comprises contacting the sample with an antibody, under conditions sufficient to form an immune complex with an endothelial progenitor cell marker, and determining a quantity of the immune complex.
    • Claim:
      22. The method of claim 21, wherein the endothelial progenitor cell marker is one or more of CD34, CD133, the vascular endothelial growth factor receptor-2 (VEGFR-2), or CD31.
    • Claim:
      23. The method of claim 1, further comprising treating the pregnant subject for preeclampsia or eclampsia.
    • Claim:
      24. The method of claim 23, wherein treating the subject comprises prescribing bed rest or administering a therapeutic agent.
    • Current U.S. Class:
      424/682
    • Current International Class:
      01; 01; 01; 61; 61
    • Accession Number:
      edspap.20110129551